SLC5A2 and neoplasm: Mean SBR for tumors in mice administered GlucoGlo alone was 2.23 a.u., significantly higher than in mice pretreated with SGLT2 inhibitor (1.01; p = 0.0002), indicating excellent tumor-specific labeling.